Conference Day Two
Conference Day Two | Thursday, December 12, 2024
7:45 am Morning Registration & Coffee
8:20 am Chair’s Opening Remarks
Targeting the Complement System for Breakthroughs in Oncology
8:30 am Antibodies, Complement, and Anti-Tumour Immunity
Synopsis
- Increasing evidence implicates compliment activities in oncology
- Targeting complement factor H
- Conceptualizing drug development targeting angiogenesis in oncology
9:00 am IgMs in Oncology & Autoimmune Diseases
Synopsis
- Using IgMs to target the complement pathways
- Increasing avidity for antibody therapeutics
- Explore potential combinational modulation of systemic, local, and intracellular complement
9:30 am Complement in Oncology
Synopsis
- Rationale for targeting complement in cancer therapy
- Preclinical and clinical data supporting complement inhibition in oncology
- Challenges and opportunities in developing complement-targeted therapies
- Combination therapies with other cancer treatments
10:00 am Panel: The Past, Present & Future of Complement in Oncology
Synopsis
- Where to target for oncology indications?
- Discussing complement dependent mechanisms in angiogenesis
- How can newly discovered complement functions be targeted for therapy?
10:30 am Morning Break
Precision Medicine in CNS Diseases: The Role of Complement Inhibition
11:00 am Complement and CNS: Role of Complement in Neural Health & Overcoming the Blood Brain Barrier
Synopsis
- Unravelling the role of complement in neuroimmunology and psychiatric indications
- Preclinically improving CNS specificity to ensure safety of targeting complement in neuroinflammatory disorders
- Overcoming the blood brain barrier through novel formulation and delivery methods
11:30 am Phase 2 Clinical Study into Empasiprubart for Multifocal Motor Neuropathy
Synopsis
- Targeting C2 to inhibit function and downstream complement activation
- Reducing tissue inflammation and adaptive immune responses in autoimmune indications
- Clinical update on Empasiprubart for MMN
12:00 pm Panel Discussion: Navigating the Complexities of Complement Inhibition in CNS Disorders
Synopsis
- Understanding the interplay between complement activation and neuroinflammation
- Differentiating between beneficial and detrimental complement pathways in CNS disease
- Balancing risks and benefits of complement inhibition in the CNS
12:30 pm Lunch Break
Complement in Ophthalmology
1:30 pm Upstream vs. Downstream Targeting in GA & AMD
Synopsis
- Discussing the advantages and disadvantages of different complement targets through an ophthalmology lens
- Delivering complement inhibitors to the eye: topical, intravitreal, or systemic?
- Future considerations for combination therapies to target multiple complement components in the eye
2:30 pm Roundtable: Optimizing Dosage and Managing Off-Target Effects to Improve Patient Outcomes
Synopsis
This interactive session gives you the opportunity to be part of the discussion, share ideas and learn from your peers. Choose the table most relevant to you, and get ready to be part of this conversation. Topics to consider:
Optimizing Dosage Studies
to Bring Safe Complement-Targeting Drugs to Patients
Examining Off Target
Effects of Complement Drugs & Potential Combinations
Delving Into Personalized Medicine Approaches for Optimizing Complement Inhibitor Therapy
Closing this session with an audience wide discussion on improving the clinical development of complement-based drugs to reduce bottlenecks from bench to bedside.
3:00 pm Afternoon Break
Innovative Horizons in Complement Drug Discovery: Future Opportunities & Next-Generation Therapies
3:30 pm Virus-derived Serpins as a Novel Modality for Specific Targeting & Competitive Inhibition
Synopsis
- Virus derived SERPINS as a potential therapeutic for complement inhibition
- Improving selectivity of targets in the complement cascades using virus like therapeutics
4:00 pm Panel Discussion: Novel Modalities & Next Generation of Complement Inhibitors
Synopsis
- Where is the next step for complement inhibitors?
- Examine the past, present, and future, of complement inhibitors for autoimmune conditions and they may fit alongside existing therapies